Viewing Study NCT06229366

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:03 PM
Ignite Modification Date: 2026-02-05 @ 8:48 PM
Study NCT ID: NCT06229366
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-22
First Post: 2024-01-03
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
Sponsor: Eli Lilly and Company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Prostate Cancer View
None Metastatic Castration-resistant Prostate Cancer View
None Oligometastatic Prostate Carcinoma View
None Hormone Sensitive Prostate Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None mCRPC View
None OmHSPC View
None Prostatic Neoplasms View
None Genital Neoplasms, Male View
None Castration Resistant Prostate Cancer View
None Hormone Sensitive Prostate Cancer View
None Oligometastatic Prostate Cancer View
None [225Ac]-PSMA-62 View
None Ac-225-PSMA-62 View
None Actinium View
None Radioligand Therapy View
None Radiopharmaceuticals View
None Urogenital Neoplasm View